Transposase-based cell line platform speeds development and raises protein yields for complex biologics

Advanced cell line development tools are helping biopharma tackle the expression and stability challenges of increasingly complex molecules such as bispecifics and trispecifics.

The article highlights a transposase-driven platform that can integrate genes more efficiently than random methods, shortening the timeline for generating high‑producing cell lines and delivering higher titers.

By pairing this technology with experienced CDMO partners, companies can reduce cost overruns and avoid delays, accelerating the path of complex biologics toward clinical testing.